Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma

• DOI: 10.4161/onci.26663
• Publication Date: 2014-01-21T19:34:48Z
• Authors: Alessandra Soriani; Cinzia Fionda; Biancamaria Ricci; Maria Luisa Iannitto; Marco Cippitelli; Angela Santoni
• Keywords: 03 medical and health sciences; 0302 clinical medicine; dnam-1; tumor immunology; multiple myeloma; nkg2d; nk cells; Author's View; 3. Good health

Malignant cells constitutively express Natural killer group 2, member D (NKG2D) or DNAX Accessory Molecule-1 (DNAM-1) ligands, yet they are often unable to trigger a robust cytotoxic cell response. It may be therapeutically useful to implement strategies aimed at increasing the density of NKG2D and DNAM-1 ligands on the surface of cancer cells, endowing them with the capacity to activate potent antitumor natural killer-cell responses.